InMed Pharmaceuticals (INM) Cash from Financing Activities (2020 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Cash from Financing Activities of $231675.0 for Q1 2026, down 92.07% year-over-year from $2.9 million in Q1 2025, and up 268.89% quarter-over-quarter from -$137178.0 in Q3 2025.
InMed Pharmaceuticals (INM) Cash from Financing Activities (2020 - 2026) Analysis & Trends
InMed Pharmaceuticals' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $231675.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 92.07% year-over-year to $231675.0; the TTM figure through Mar 2026 stood at $8.3 million (up 101.84% YoY), while the FY2025 annual figure was $12.3 million, up 163.66% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $231675.0, up from -$137178.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $8.2 million in Q2 2025, with the low at -$137178.0 in Q3 2025.
- The 5-year median for Cash from Financing Activities is $588380.0 (2024), against an average of $2.3 million.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities sank 117.31% in 2023, then soared 4644531.25% in 2025.
- InMed Pharmaceuticals' Cash from Financing Activities stood at $5.3 million in 2022, then sank by 101.2% to -$63697.0 in 2023, then soared by 631.46% to $338521.0 in 2024, then tumbled by 140.52% to -$137178.0 in 2025, then surged by 268.89% to $231675.0 in 2026.
- Business Quant data shows INM's Cash from Financing Activities at $231675.0 in Q1 2026, -$137178.0 in Q3 2025, and $8.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.36 Mn | 1.11 Mn | - | 231,675.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 231,675.00 |
| Mar 31, 2026 | 231,675.00 |
| Sep 30, 2025 | -137,178.00 |
| Sep 30, 2025 | -137,178.00 |
| Jun 30, 2025 | 8.17 Mn |
| Jun 30, 2025 | 8.17 Mn |
| Mar 31, 2025 | 2.92 Mn |
| Mar 31, 2025 | 2.92 Mn |
| Dec 31, 2024 | 338,521.00 |
| Dec 31, 2024 | 338,521.00 |
| Sep 30, 2024 | 838,239.00 |
| Sep 30, 2024 | 838,239.00 |
| Jun 30, 2024 | 176.00 |
| Jun 30, 2024 | 176.00 |
| Mar 31, 2023 | -63,697.00 |
| Mar 31, 2023 | -63,697.00 |
| Dec 31, 2022 | 5.32 Mn |
| Dec 31, 2022 | 5.32 Mn |
| Sep 30, 2022 | 5.43 Mn |
| Sep 30, 2022 | 5.43 Mn |